Business
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
FEATURED STORIES
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The company uses computational modeling of cell behavior to treat disease, instead of going after a molecular target, redefining drug discovery through its cell-centric approach.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.
Mallon announced his resignation from Ironwood earlier this month to take on a new leadership opportunity and “pursue multiple passions.”
BMS is looking to hire “several hundred employees over the next few years,” all working to ensure the production of both their clinical and commercial cell therapies.
The prosecution alleged that sometime in 2018, Holmes destroyed a database called the Laboratory Information System (LIS), which contained three years’ worth of accuracy and failure rates of Theranos tests.
Life sciences companies across the globe are raking in investment dollars to advance drug programs.
Cancer detection company GRAIL has entered into an agreement with Quest Diagnostics that sees Quest providing phlebotomy services to support GRAIL’s multi-cancer early detection blood test Galleri™.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 23, 2021.